JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice - ScienceDirect
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer - Lingzhi Hong, Jianjun Zhang, John V. Heymach, Xiuning Le, 2021
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
Capmatinib (INCB28060) | 99.99%(HPLC) | Selleck | c-Met inhibitor
Capmatinib for the treatment of non-small cell lung cancer
Frontiers | HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Frontiers | Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells - Han - 2017 - Molecular Oncology - Wiley Online Library
Overcoming therapy resistance in EGFR-mutant lung cancer | Nature Cancer
The METeoric rise of MET in lung cancer - Friedlaender - 2020 - Cancer - Wiley Online Library
The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity | Request PDF
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Mechanisms of Action | Investigational Inhibitors in Lung Cancer
Amivantamab mechanisms of action | Download Scientific Diagram
Mechanisms of Action | Investigational Inhibitors in Lung Cancer
The role of MET in chemotherapy resistance | Oncogene
Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications | JACC: Clinical Electrophysiology
